Amneal Pharmaceuticals (AMRX) AI Stock Analysis

• Market Cap: $3.56B
• Dividend Yield: N/A
• Average Volume (3M): 1.57M
• Price to Earnings (P/E): 788.2
• Beta (1Y): 0.95
• Revenue Growth: 9.50%
• EPS Growth: N/A
• Country: US
• Employees: 8,300
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.17
• Shares Outstanding: 314,079,300
• 10 Day Avg. Volume: 1,199,751
• 30 Day Avg. Volume: 1,572,441
• PEG Ratio: 1.00
• Price to Book (P/B): -22.40
• Price to Sales (P/S): 0.88
• P/FCF Ratio: 10.06
• Enterprise Value/Market Cap: 1.45
• Enterprise Value/Revenue: 1.76
• Enterprise Value/Gross Profit: 4.80
• Enterprise Value/Ebitda: 9.31
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 63 Neutral
• Price Target: $10.50 ▲(2.54% Upside)

Amneal Pharmaceuticals' strong earnings call performance and positive technical indicators are offset by a high P/E ratio and challenges in profitability and cash flow growth. The company's strategic initiatives and improved leverage are positive, but valuation concerns and competitive pressures in biosimilars present risks.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective product strategy, enhancing long-term business sustainability.

Product Portfolio Expansion

Expanding the product portfolio diversifies revenue streams and strengthens market position, supporting long-term growth and resilience.

Debt Refinancing and Leverage Reduction

Refinancing and reducing leverage enhances financial stability and flexibility, allowing for strategic investments and growth opportunities.

Negative Factors

Gross Margin Decline

Declining gross margins can pressure profitability, indicating potential challenges in cost management and pricing power.

Biosimilars Competition

Intense competition and high costs in biosimilars could limit market share and profitability, impacting long-term growth prospects.

Uncertainty in Metsera Partnership

Uncertainty in partnerships could disrupt strategic plans and revenue streams, affecting long-term stability and growth.

Amneal Pharmaceuticals Business Overview & Revenue Model

Company Description

Amneal Pharmaceuticals, Inc. is a global pharmaceutical company based in the United States that specializes in the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The company operates primarily in the prescription drug market and focuses on various therapeutic areas, including central nervous system, infectious disease, endocrinology, and pain management. Amneal's portfolio includes a wide range of generic medications, as well as proprietary branded products, positioning it as a significant player in the pharmaceutical industry.

How the Company Makes Money

Amneal Pharmaceuticals generates revenue primarily through the sale of generic and specialty pharmaceuticals. The company's revenue model includes several key streams: sales of generic drugs, which make up a substantial portion of its income, and sales from branded products, including niche and complex generics. Amneal has established partnerships with various healthcare providers, distributors, and pharmacy benefit managers, which facilitate the distribution of its products. Additionally, the company may engage in licensing agreements and collaborations with other pharmaceutical firms, contributing to its revenue through upfront payments, royalties, and milestone payments. Factors such as market demand for affordable medications, the company's ability to successfully launch new products, and the maintenance of production efficiency significantly impact its earnings.

Amneal Pharmaceuticals Financial Statement Overview

Summary

Amneal Pharmaceuticals shows steady revenue growth and efficient cost management, reflected in a healthy gross profit margin. However, challenges remain with low net profit margins and moderate operational efficiency. The balance sheet indicates improved leverage but limited profitability from equity. Strong cash flow generation is offset by negative free cash flow growth.

Income Statement

Amneal Pharmaceuticals shows a modest revenue growth rate of 2.88% in the TTM, indicating steady sales performance. The gross profit margin is healthy at 36.76%, reflecting efficient production and cost management. However, the net profit margin is low at 0.20%, suggesting challenges in translating revenue into profit. The EBIT and EBITDA margins are moderate at 10.74% and 18.93%, respectively, indicating reasonable operational efficiency but room for improvement in profitability.

Balance Sheet

The company's debt-to-equity ratio has improved significantly to 0.15 in the TTM, demonstrating a reduction in leverage and improved financial stability. However, the return on equity is low at 5.06%, indicating limited profitability from shareholders' investments. The equity ratio stands at 22.78%, suggesting a moderate level of financial stability but potential vulnerability to financial fluctuations.

Cash Flow

Operating cash flow is strong with a coverage ratio of 0.38, indicating good cash generation relative to net income. However, free cash flow growth is negative at -6.73%, highlighting challenges in maintaining cash flow growth. The free cash flow to net income ratio is 0.75, suggesting that a significant portion of earnings is converted to free cash flow, but there is room for improvement.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.93B	2.79B	2.39B	2.21B	2.09B	1.99B
Gross Profit	1.08B	1.02B	820.57M	791.46M	783.95M	628.39M
EBITDA	555.65M	439.77M	399.76M	150.43M	401.10M	345.61M
Net Income	5.90M	-116.89M	-83.99M	-129.99M	10.62M	91.06M
Balance Sheet
Total Assets	3.60B	3.50B	3.47B	3.80B	3.94B	4.01B
Cash, Cash Equivalents and Short-Term Investments	201.25M	112.42M	93.74M	27.80M	248.96M	341.38M
Total Debt	2.69B	2.59B	2.75B	2.85B	2.88B	2.94B
Total Liabilities	2.78B	3.55B	3.45B	3.59B	3.57B	3.66B
Stockholders Equity	819.93M	-109.27M	19.78M	298.42M	360.34M	344.93M
Cash Flow
Free Cash Flow	244.82M	243.18M	276.39M	-25.50M	189.18M	312.81M
Operating Cash Flow	327.75M	295.10M	345.58M	65.10M	241.82M	379.00M
Investing Cash Flow	-82.87M	-63.00M	-69.19M	-174.31M	-194.18M	-317.55M
Financing Cash Flow	-82.61M	-211.79M	-212.57M	-106.62M	-138.12M	131.81M

Amneal Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 10.24
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMRX, the sentiment is Positive. The current price of 10.24 is below the 20-day moving average (MA) of 10.50, above the 50-day MA of 10.16, and above the 200-day MA of 8.61, indicating a bullish trend. The MACD of 0.39 indicates Negative momentum. The RSI at 64.72 is Neutral, neither overbought nor oversold. The STOCH value of 86.27 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AMRX.

Amneal Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMPH	67 Neutral	$1.13B	9.00	18.32%	―	1.37%	-18.10%
AMRX	63 Neutral	$3.56B	788.19	―	―	9.50%	―
ANIP	62 Neutral	$1.96B	―	-2.82%	―	38.68%	-160.14%
SUPN	55 Neutral	$2.64B	―	-1.86%	―	4.54%	-130.59%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALVO	48 Neutral	$1.53B	27.20	―	―	98.37%	―
PRGO	48 Neutral	$2.78B	―	-0.65%	5.55%	-2.55%	66.00%

Amneal Pharmaceuticals Corporate Events

Amneal Pharmaceuticals Reports Strong Q3 Growth Amid Challenges

Amneal Pharmaceuticals’ recent earnings call highlighted a robust financial performance, marked by growth across its key segments and an upward revision of its financial guidance. Despite these positive developments, the company acknowledged challenges in gross margins and potential uncertainties in its partnerships.

Amneal Pharmaceuticals Reports Strong Q3 2025 Results

Amneal Pharmaceuticals, Inc., headquartered in Bridgewater, NJ, is a global biopharmaceutical company that develops, manufactures, and distributes a diverse portfolio of over 290 pharmaceutical products, focusing on affordable medicines and specialty branded pharmaceuticals, primarily in the United States.

Amneal Pharmaceuticals Reports Strong Q3 2025 Results

Amneal Pharmaceuticals reported its financial results for the third quarter of 2025, with net revenue reaching $785 million, a 12% increase from the previous year, and a net income of $2 million. The company’s growth was driven by key branded products like CREXONT® and new launches such as BREKIYA® in the migraine space, alongside a strong performance in their Affordable Medicines segment. Amneal updated its 2025 full-year guidance, reflecting increased expectations for adjusted EBITDA and diluted EPS, highlighting the company’s strategic positioning and momentum as it enters 2026.

The most recent analyst rating on (AMRX) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Amneal Pharmaceuticals stock, see the AMRX Stock Forecast page.

Mycophenolate Pregnancy Registry: Key Insights for Investors

The Mycophenolate Pregnancy Registry, officially titled the same, is a prospective, observational study aimed at gathering data on mycophenolate exposure during pregnancy and its outcomes. This study, sponsored by Genentech, Inc., with collaborators including Amneal Pharmaceuticals, Alkem Laboratories, Concord Biotech, and Sandoz, seeks to understand the impact of mycophenolate on pregnancy, fetal, and infant outcomes, which is crucial for evaluating the safety of mycophenolate formulations like CellCept and Myfortic.

Amneal Pharma’s CREXONT Study: A Potential Game-Changer for Parkinson’s Treatment?

Amneal Pharmaceuticals, in collaboration with Impax Laboratories, is currently recruiting participants for an open-label Phase 4 study titled ‘Open-Label Phase 4 Study of CREXONT® (Carbidopa and Levodopa) Extended Release Capsules in Parkinson’s Disease Patients.’ The study aims to evaluate the efficacy and safety of CREXONT, an extended-release capsule containing Carbidopa and Levodopa, under real-world conditions for patients with Parkinson’s Disease. This study is significant as it seeks to provide insights into the treatment’s performance outside of controlled clinical settings.

Amneal Pharma Reports Strong Q2 2025 Results

Amneal Pharmaceuticals, Inc., headquartered in Bridgewater, NJ, is a global biopharmaceutical company that develops, manufactures, and distributes a diverse portfolio of over 280 pharmaceutical products, focusing on affordable medicines and specialty pharmaceuticals primarily in the United States.

Amneal Pharma’s Optimistic Q2 Earnings Call Highlights

Amneal Pharmaceuticals’ recent earnings call conveyed an optimistic sentiment, underscored by robust revenue and EBITDA growth, successful product launches, and strategic progress in the biosimilars sector. Despite these positive developments, the company acknowledged several challenges, including a decline in AvKARE revenues, potential tariff impacts, and uncertainties in the RYTARY generics market.

Amneal Pharmaceuticals Reports Strong Q2 2025 Results

Amneal Pharmaceuticals reported strong financial results for the second quarter of 2025, with a net revenue of $725 million, marking a 3% increase from the previous year. The company also announced a successful debt refinancing, which reduces interest costs and extends maturities, positioning Amneal for long-term growth. The quarter was highlighted by the commercial success of CREXONT® for Parkinson’s disease and the FDA approval of Brekiya® autoinjector for migraines, contributing to a 23% increase in specialty net revenue. Amneal raised its full-year 2025 financial guidance, reflecting confidence in its diversified pharmaceutical business and growth strategies.

The most recent analyst rating on (AMRX) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Amneal Pharmaceuticals stock, see the AMRX Stock Forecast page.